Cardiome Pharma Corp.'s strong Phase III data in June with intravenous vernakalant for atrial fibrillation (AF) or atrial flutter after coronary artery bypass graft (CABG) surgery may have opened the door for off-label use in new-onset AF, and also may have cleared a somewhat smoother regulatory path for the product. (BioWorld Financial Watch) Read More
